{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:48:34Z","timestamp":1791233314496,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jpba.2021.113921","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T09:46:39Z","timestamp":1611740799000},"page":"113921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds"],"prefix":"10.1016","volume":"196","author":[{"given":"Juha","family":"Jyrk\u00e4s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Tolonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.113921_bib0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic approaches to optimizing peptide ADME properties","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2021.113921_bib0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jpba.2021.113921_bib0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jps.2600750211","article-title":"Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration","volume":"75","author":"Sennello","year":"1986","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2021.113921_bib0020","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1093\/humrep\/13.9.2392","article-title":"Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers","volume":"13","author":"Duijkers","year":"1998","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.jpba.2021.113921_bib0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00003088-198611020-00002","article-title":"Clinical pharmacokinetics of cyclosporin","volume":"11","author":"Ptachinski","year":"1986","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2021.113921_bib0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/1389200023337630","article-title":"Review: Metabolism of immunosuppressant drugs","volume":"3","author":"Kelly","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jpba.2021.113921_bib0035","first-page":"1","article-title":"A comprehensive review on current advances in peptide drug development and design","volume":"20","author":"Lee","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpba.2021.113921_bib0040","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cbic.201500312","article-title":"Peptide backbone composition and protease susceptibility: impact of modification type, position, and tandem substitution","volume":"17","author":"Werner","year":"2016","journal-title":"Chembiochem."},{"key":"10.1016\/j.jpba.2021.113921_bib0045","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/dta.2256","article-title":"Determination of GnRH and its synthetic analogues\u2019 abuse in doping omcontrol: small bioactive peptide UPLC\u2013MS\/MS method extension by addition of in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameter fluctuations as suitable","volume":"10","author":"Zvereva","year":"2018","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2021.113921_bib0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0090-9556(24)14996-3","article-title":"Disposition and metabolism of cetrorelix, a potent luteinizing hormone- releasing hormone antagonist, in rats and dogs","volume":"28","author":"Schwahn","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2021.113921_bib0055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jprot.2016.08.016","article-title":"Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction","volume":"149","author":"Zvereva","year":"2016","journal-title":"J. Proteomics"},{"key":"10.1016\/j.jpba.2021.113921_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/psc.2710","article-title":"In vitro models for metabolic studies of small peptide hormones in sport drug testing","volume":"21","author":"Esposito","year":"2015","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.jpba.2021.113921_bib0065","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/clpt.1988.87","article-title":"Cyclosporin metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs","volume":"43","author":"Kronbach","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2021.113921_bib0070","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2174\/1389200219666180628171531","article-title":"Metabolism of peptide drugs and strategies to improve their metabolic stability","volume":"19","author":"Yao","year":"2018","journal-title":"Curr. Drug Metab."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521000339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521000339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:10:33Z","timestamp":1760001033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521000339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":14,"alternative-id":["S0731708521000339"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.113921","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.113921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113921"}}